Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 4,647

Document Document Title
WO/2020/180876A1
The present application provides a compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions containing these compounds, and methods of using these compounds for treating cancer, ...  
WO/2020/168149A1
Disclosed are compounds of Formula (I): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein Q is: (i) halo, cyano, hydroxyl, NRxRx, C(O)OH, C(O)NH2, C1-6 alkyl substituted with zero to 6 R1a, ...  
WO/2020/167994A1
The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or prodrug thereof, and methods of making and using thereof.  
WO/2020/168152A2
Disclosed are compounds of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein Q is a 5-membered heterocyclyl or 5-membered heteroaryl having 1 to 4 heteroatoms independently selec...  
WO/2020/157069A1
The present disclosure relates to compounds of Formula (I): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inh...  
WO/2020/156298A1
Disclosed by the present invention is an application of a malononitrile compound as represented by general formula I as a bactericide. See the description for the definition of each substituent in the formula. The compound represented by...  
WO/2020/156106A1
Heterocyclic aryl formamides or a salt thereof, a preparation method, a weeding composition, and an application. The structural formula of the heterocyclic aryl formamide compound or the salt thereof is as shown in formula I, and the com...  
WO/2020/152718A1
The present invention provides polymorphic form M1, M2 and M3 of ozanimod. It also provides amorphous solid dispersions of ozanimod.  
WO/2020/148403A1
The present invention is directed to 5-membered heteroaryl compounds containing a hydroxamate moiety of Formula I, pharmaceutically acceptable salts or solvates thereof, and their use as sensitizers for chemotherapy of malignant tumors.  
WO/2020/076274A3
The present invention is related to unique caffeic acid phenethyl ester (CAPE) analogues, methods for preparation of said molecules, and the usage of said unique molecules in the preparation of a pharmaceutical composition that is to be ...  
WO/2020/138228A1
Provided are a jasmonic acid endogeny promoting agent and a method for promoting jasmonic acid endogeny using the same, said agent containing a compound shown in formula (1) or a salt thereof as an active ingredient. In formula (1), R1 a...  
WO/2020/138935A1
The present invention relates to a novel compound and a medicinal use of the novel compound. In particular, the present invention relates to a novel compound useful for the treatment and/or prevention of muscular dystrophy, including Duc...  
WO/2020/127960A1
The present invention relates to disubstituted alkyne derivatives. These compounds are useful for the prevention and/or treatment of several medical conditions including hyperproliferative disorders and diseases.  
WO/2020/127685A1
The present invention relates to a compound according to formula I (I) and pharmaceutically acceptable salts, hydrates, or solvates thereof. The invention further relates to said compounds for use in therapy, to pharmaceutical compositio...  
WO/2020/128675A1
Substances effective against tuberculosis based on substituted 1,2,4-oxadiazoles of general formula I, where Y = S or CH2 and R = phenyl- or phenyl- substituted in positions 2, 3, 4, and 5 by one or several electron-acceptor groups or el...  
WO/2020/115200A1
The presented invention relates to a process for preparation of compound of formula (1) or a salt thereof (i.e.) ozanimod : (1). The invention also relates to intermediates used in the process.  
WO/2020/108518A1
The present invention relates to the technical field of pesticides, and specifically relates to an N-(1, 3, 4-oxadiazole-2-yl)aryl formamides or a salt thereof, a preparation method therefor, a herbicidal composition and a use thereof. T...  
WO/2020/100959A1
The purpose of the present invention is to provide a compound having PIM inhibiting activity. Examples of the compound according to the present invention include a 1,3,4-oxadiazolone compound represented by formula [1], a pharmaceutica...  
WO/2020/033413A3
RAS modulating compounds and methods of using the same are provided. The compounds find use in modulating the activity of a target RAS in a sample. The target RAS can be a mutant RAS that is implicated in a disease of interest. In some c...  
WO/2020/083336A1
The present invention relates to the field of medicinal chemistry, and relates to a class of 1,3,4-oxadiazole-2-cyclobutyl compounds or a pharmaceutically acceptable salt, hydrate, solvate or crystal thereof, and a preparation method the...  
WO/2020/085373A1
The present invention provides a novel compound which has activating activity selective for ERβ. A compound represented by formula (1) or a salt thereof. (In the formula, R1 represents a cycloalkyl group having 3-8 carbon atoms, an alke...  
WO/2020/078732A1
Compounds of formula (I): (I) wherein the substituents are as defined in claim 1, useful as pesticides, especially as fungicides.  
WO/2020/081143A1
Pyrrole and pyridine derivatives and methods of synthesizing the derivatives/analogs are provided. In particular, the compounds are useful for the treatment of antiviral infections such as HIV and influenza.  
WO/2020/070611A1
The present invention relates to novel oxadiazoles of Formula (I) wherein, R1, L1, A1, A2, A3, A4, L2 and R2 are as defined in the detailed description. The present invention also relates to a combination or a composition comprising the ...  
WO/2020/064818A1
Industrially viable and advantageous processes for the preparation of Ozanimod are described. The invention also discloses the intermediates obtained in the process.  
WO/2019/109067A3
The present disclosure provides creatine prodrug analogs and their compositions useful for the treatment of creatine deficiencies.  
WO/2020/060963A1
The disclosure provides 1, 3, 4-oxadiazole derivatives useful for stemming bleeding and for treating cancer.  
WO/2020/060299A1
Disclosed in the present invention is an oxadiazole compound and pharmaceutically useful salts thereof. The compound and pharmaceutically useful salts thereof are especially suitable for the treatment of nervous system diseases such as e...  
WO/2020/053334A1
The present invention relates to an improved process for preparation of Ozanimod (I) or pharmaceutically acceptable salts thereof. The present invention also relates to an improved process for preparation of (S)-l-amino-2,3-dihydro- 1H-i...  
WO/2020/047668A1
Provided herein are Myc-Max inhibitory compounds having the structure of Formula (I) and compositions thereof for use in the treatment of cancer. In particular, the Myc-Max inhibitory compounds may be useful for the treatment of cancers ...  
WO/2020/043866A1
A compound for use in the treatment of a disease ameliorated by the inhibition of Notum of formula (I): (I)  
WO/2020/030093A1
A pharmaceutical composition containing an M-diamide compound and an application thereof. The pharmaceutical composition comprises an active ingredient A and an active ingredient B, the active ingredient A is an M-diamide compound having...  
WO/2020/030092A1
A pharmaceutical composition containing an m-diamide compound and an application thereof. The pharmaceutical composition comprises an active component A and an active component B, wherein the active component A is the m-diamide compound ...  
WO/2020/030096A1
A drug composition containing an M-diamide compound and application of the drug composition. The drug composition comprises an effective constituent A and an effective constituent B; the effective constituent A is the M-diamide compound ...  
WO/2020/030094A1
Provided are a pharmaceutical composition comprising a meta-diamide compound and the use thereof. The pharmaceutical composition includes an active ingredient A and an active ingredient B, wherein the active ingredient A is a meta-diamid...  
WO/2020/033413A2
RAS modulating compounds and methods of using the same are provided. The compounds find use in modulating the activity of a target RAS in a sample. The target RAS can be a mutant RAS that is implicated in a disease of interest. In some c...  
WO/2020/032071A1
Development of a novel agricultural or horticultural bactericide is desired because considerable damage by diseases is still caused to agricultural and horticultural production and the like and because of, for example, damage by diseases...  
WO/2020/019994A1
Disclosed is a compound having a neuroprotective effect, a preparation method therefor and a use thereof. In particular, disclosed is a compound as shown in general formula A or a pharmaceutically acceptable salt thereof. Also disclosed ...  
WO/2020/015745A1
Provided are a compound III serving as an LSD1 inhibitor and a polymorph thereof, as well as an application of the compound and the polymorph thereof in the preparation of drugs for treating LSD1-associated diseases.  
WO/2019/171234A9
The present invention relates to novel heterocyclic compound of Formula (I), (I) wherein, Het, L1, A, L2 and R12 are as defined in the detailed description, for use as fungicides.  
WO/2020/001067A1
Provided are m-diamide compounds and a preparation method therefor and the use thereof. The m-diamide compounds have a structure represented by formula I. The m-diamide compounds of the present invention can have a high insecticidal acti...  
WO/2020/005888A1
Provided are compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2, Y1, Y2, L1, and G1 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (...  
WO/2020/006177A1
Disclosed herein are small molecule Vascular Adhesion Protein- 1 (VAP-1) modulator compositions, pharmaceutical compositions, the use and preparation thereof.  
WO/2020/005313A1
The invention provides methods and compositions for treating cancers and myeloproliferative disorders using sphingosine kinase-1 inhibitors, such as SK1-I, and selective sphingosine-1-phosphate receptor agonists, such as ozanimod.  
WO/2020/005887A1
Provided are compounds of Formula (I) or a pharmaceutically acceptable salt thereof, wherein X, R1, R2, and R3 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or a p...  
WO/2019/243358A1
The present invention relates to compounds Formula (I): wherein Q, R2, R3, R4 and R5 are as defined herein. The invention further relates to compositions comprising said compounds, and methods of controlling weeds using said compounds an...  
WO/2019/232724A1
The present invention relates compounds of Formula (I) - (V), as well as their preparation and uses, and further relates pharmaceutical compositions comprising these compounds and their uses as nuclear transport modulators. The present i...  
WO/2019/228289A1
Disclosed is a substituted oxadiazole compound having a novel structure and represented by general formula I. Each substituent in the formula is defined in the specification. The compound of general formula I has excellent microbicidal a...  
WO/2019/084463A8
The present disclosure is concerned with oxadiazole and thiadiazole analogs that are capable of inhibiting TGF-β and methods of treating cancers such as, for example, multiple myeloma and a hematologic malignancy, and methods of treatin...  
WO/2019/227202A1
Disclosed are pharmaceutical salts and co-crystals of pentoxifylline, clonidine and linsidomine with caffeic acid, protocatechuic acid or α-lipoic acid, and method for preparing thereof. Also disclosed are topical compositions comprisin...  

Matches 1 - 50 out of 4,647